Exelixis (EXEL) Earns Outperform Rating from William Blair

Exelixis (NASDAQ:EXEL)‘s stock had its “outperform” rating reaffirmed by equities researchers at William Blair in a research report issued on Monday.

A number of other brokerages have also recently issued reports on EXEL. BidaskClub upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Oppenheimer reiterated a “hold” rating on shares of Exelixis in a research note on Thursday, January 4th. Cann reiterated a “hold” rating on shares of Exelixis in a research note on Thursday, January 4th. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price target on the stock in a research note on Tuesday, January 2nd. Finally, Needham & Company LLC upped their price target on shares of Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, October 17th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $32.13.

Exelixis (NASDAQ:EXEL) opened at $28.75 on Monday. The stock has a market cap of $8,350.00, a PE ratio of 57.57, a P/E/G ratio of 0.79 and a beta of 1.84. Exelixis has a one year low of $18.03 and a one year high of $32.50.

In other Exelixis news, Director Alan M. Garber sold 15,000 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total value of $454,500.00. Following the completion of the transaction, the director now owns 64,829 shares of the company’s stock, valued at approximately $1,964,318.70. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.10% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of EXEL. Mark Sheptoff Financial Planning LLC purchased a new position in Exelixis in the 3rd quarter worth about $120,000. Sigma Planning Corp purchased a new stake in shares of Exelixis during the 4th quarter valued at about $208,000. American International Group Inc. purchased a new stake in shares of Exelixis during the 4th quarter valued at about $208,000. Fisher Asset Management LLC purchased a new stake in shares of Exelixis during the 3rd quarter valued at about $213,000. Finally, Klingenstein Fields & Co. LLC purchased a new stake in shares of Exelixis during the 4th quarter valued at about $213,000. 81.43% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/12/exelixis-exel-earns-outperform-rating-from-william-blair.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply